OxThera
Stockholm
About OxThera
OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $87.6M
- Funding stage: Late Stage Venture
- Last round: Series D (Nov 2016)
- Website: oxthera.com
- Phone: (468) 660-0223
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/oxthera-66615 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.